Articles tagged with: SVNT
Savient Pharma rises high (NASDAQ:SVNT)
On a late Friday afternoon, shares of Savient Pharmaceuticals bounced back as analysts for Oppenheimer and Co. raised his views on Savient Pharmaceuticals and its new chronic gout drug candidate Krystexxa.
Light At The End Of The Tunnel For Treatment Failure Gout Sufferers? (SVNT)
There may be a light at the end of the tunnel for treatment failure gout (TFG) sufferers.Savient PharmaceuticalsInc. (NASDAQ SVNT) is responsible for shining that light, in the form of their ambitious drug Krystexxa. TFG …
